Drug Approval | June 02, 2026
Bristol Myers Squibb wins EU approval for Opdivo-based frontline treatment in advanced hodgkin lymphoma
The approval is supported by results from the Phase 3 SWOG 1826 trial
The approval is supported by results from the Phase 3 SWOG 1826 trial
Initiatives at Churchgate Station and Mahindra & Mahindra focus on early detection, public education, and tobacco-related cancer prevention
Approved as a web-based pre-diagnostic tool for suspected rare diseases and classified as a Class A (non-sterile and non-measuring) medical device
The therapy also delivered significant improvements in key liver enzyme markers
World MS Day 2026 conclave brings together MPs, neurologists, disability rights advocates and insurance stakeholders to push for reforms in healthcare access, disability recognition and social protection
The aflibercept biosimilar, referencing Eylea, becomes the company’s fifth directly commercialized biosimilar in Europe, expanding access to ophthalmology treatments
We have the chance to build an IP estate that goes hand in hand with our generic pharmaceutical strength and build proprietary biological platforms
Increasing syphilis cases, stronger STI surveillance initiatives, and growing emphasis on early diagnosis are expected to support sustained demand
This marks one of the most closely watched oncology readouts at this year’s medical congress
MeziKd delivered stronger response rates across multiple patient groups, including those receiving second- and third-line treatment and patients with higher-risk disease
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
